Zai Lab Ltd (9688) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Zai Lab Ltd stock HK$16.10, price HK$19.18, that is 16.1% below the price, quality 48 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Zai Lab Ltd
9688 · HKExpensive (fair value 16% below the price), weak company and price moving sideways: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.
How to read this chart
60‑month range HK$10.62 – HK$136.50 · fair‑value band HK$12.07 – HK$20.12 · the HK$19.18 price screens above the HK$16.10 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.
Every Wednesday you see whether Zai Lab is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
Show moreShow less
Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Stock analysis
Zai Lab Ltd (9688) currently trades at HK$19.18, while our estimate is HK$16.10, 16% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: HK$12.07 (bear) to HK$20.12 (bull), the price of HK$19.18 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Zai Lab Ltd reported revenue of $461M in FY2025 versus $144M in FY2021, a compound +33.7%/yr. Reported net income was −$176M in FY2025.
Key figures
Market cap HK$24.9B (≈ $3.2B) Mid · P/S ratio 60.2 · EPS (TTM) HK$−0.1900 · Net margin −38.1% · Return on equity −30.0% · Return on assets (EBIT) −31.1% (5-year average) · Operating margin −58.2% · Revenue (TTM) $442M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 11% below its 52-week high and 54% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −16%, 9688 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Zai Lab Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Fair value gap by industry
- Return on assets by industry
- Stock screener with 62 metrics
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs 9688 |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs 9688 |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs 9688 |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs 9688 |
| CSL Limited CSL | A$202.52 | A$186.49 | −8% | vs 9688 |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs 9688 |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs 9688 |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs 9688 |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs 9688 |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs 9688 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Zai Lab Ltd (9688) overvalued or undervalued?
What is the fair value of 9688?
What is the quality score of 9688?
What is the price target for Zai Lab Ltd (9688)?
What is the Zai Lab Ltd stock forecast for 2026?
What is the revenue of Zai Lab Ltd (9688)?
What is the intrinsic value of Zai Lab Ltd (9688)?
Is Zai Lab Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 9688?
How much is Zai Lab Ltd worth?
What do the bullish and bearish scenarios say about 9688?
How solid is the balance sheet of Zai Lab Ltd (9688)?
How far is 9688 from its 52-week high?
Which stocks are comparable to Zai Lab Ltd?
Is Zai Lab Ltd stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Zai Lab Ltd (9688)?
What should I pay attention to with Zai Lab Ltd right now?
Key figures of Zai Lab Ltd
How large is the market capitalisation of Zai Lab Ltd (9688)?
What is the P/S ratio of Zai Lab Ltd (9688)?
What are the earnings per share of Zai Lab Ltd (9688)?
What is the net margin of Zai Lab Ltd (9688)?
What is the return on equity of Zai Lab Ltd (9688)?
What is the EBIT return on assets of Zai Lab Ltd (9688)?
What is the operating margin of Zai Lab Ltd (9688)?
How fast is revenue growing at Zai Lab Ltd (9688)?
How much free cash flow does Zai Lab Ltd (9688) generate?
How much net cash does Zai Lab Ltd (9688) hold?
Watch Zai Lab Ltd in the live analysis
One click puts Zai Lab Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.